Holdenrieder: #oncobeam #genomewebinar Asks: do plasma and tissue correlate? Prognostic for pt outcome (OS and PFS… https://t.co/Ja8cY8uNmS
11:37am May 8th 2019 via Twitter Web Client
Holdenrieder: #oncobeam #genomewebinar 54 pts with adv panc ca; first-line gemcitabine-based chemo. Tissue + Plasm… https://t.co/uOLcDz7s18
11:36am May 8th 2019 via Twitter Web Client
Holdenrieder: #oncobeam #genomewebinar Shows chart of freq of KRAS, tp53 mutations in panc cancer. Points to prosp… https://t.co/V3BUkK1SgV
11:35am May 8th 2019 via Twitter Web Client
Holdenrieder: #oncobeam #genomewebinar In Pancreatic cancer - not as frequent but high mortality. Often detected l… https://t.co/NFwMgKF5VA
11:34am May 8th 2019 via Twitter Web Client
Holdenrieder: #oncobeam #genomewebinar If the mut load is needed, you need to 'go quantitative'. Nice (long!) list… https://t.co/Kj5y37pvBS
11:33am May 8th 2019 via Twitter Web Client
Holdenrieder: #oncobeam #genomewebinar BEAMing has high concordance - four references where concordance >90%. Indi… https://t.co/Hc6R315
11:32am May 8th 2019 via Twitter Web Client
Holdenrieder: #oncobeam #genomewebinar Shows Bettegowda et al figure of percent of cancer types that have detectab… https://t.co/8VfdiVxY1Y
11:31am May 8th 2019 via Twitter Web Client
Holdenrieder: #oncobeam #genomewebinar Describes liquid biopsy as 'liquid profiling' - as it is looking at markers… https://t.co/etr6P5HMJu
11:30am May 8th 2019 via Twitter Web Client
Holdenrieder: #oncobeam #genomewebinar Nice review of markers by tumor tpe, and description of tumor heterogeneity… https://t.co/BthwRQ4b7F
11:29am May 8th 2019 via Twitter Web Client
Stefan Holdenrieder (Technical University of Munich) OncoBEAM for ctDNA in monitoring of pancreatic cancer. Starts… https://t.co/5ViaGfin74
11:28am May 8th 2019 via Twitter Web Client
Lipson: #oncobeam #genomewebinar Concl: ctDNA useful melanoma biomarker.
11:27am May 8th 2019 via Twitter Web Client
Lipson: #oncobeam #genomewebinar Shows example of 68yo female on pembro for met melanoma baseline 0.95% ctDNA, 1.5c… https://t.co/y2Np7TZ9Cr
11:25am May 8th 2019 via Twitter Web Client
Lipson: #oncobeam #genomewebinar Shows timeline of EDA in circulation prior to imaging in 4 pts. Ave 24 weeks before detection via imaging.
11:23am May 8th 2019 via Twitter Web Client
Lipson: #oncobeam #genomewebinar 4/8 pts PD coincident of EDA in ctDNA; other 4 predicted radiographic progression… https://t.co/t3c5PPGzjt
11:22am May 8th 2019 via Twitter Web Client
Lipson: #oncobeam #genomewebinar Cohort C: n=36, 30 evaluable. All treated, charted mut status, collected serial ct… https://t.co/ff5rHYotd4
11:21am May 8th 2019 via Twitter Web Client
Lipson: #oncobeam #genomewebinar Cohort B: n=31, 29 evaluable. Recurrent w/1 of 6 hotspot muts: Locoregoinal spread… https://t.co/XJH3Wt46cs
11:19am May 8th 2019 via Twitter Web Client
Lipson: #oncobeam #genomewebinar Cohort A concl: of 57 pt, 35mm ideal cutoff, two pts unmeasured BRAF in tissue but… https://t.co/0aL0C7YA6M
11:17am May 8th 2019 via Twitter Web Client
Lipson: #oncobeam #genomewebinar One pt no BRAF mut in tissue; another insuff quality: both ctDNA revealed bRAF; bo… https://t.co/0xQR3XTtOE
11:16am May 8th 2019 via Twitter Web Client
Lipson: #oncobeam #genomewebinar Shows burden of 9 pts w/smaller tumors and location - visceral, lung etc. Chart fr… https://t.co/g9gjv4LeIP
11:15am May 8th 2019 via Twitter Web Client
Lipson: #oncobeam #genomewebinar Of the five + in tumor but neg in ctDNA: low tumor burden (small size). ROC of coh… https://t.co/qFKaeGoUno
11:14am May 8th 2019 via Twitter Web Client
Lipson: #oncobeam #genomewebinar 61 pts of cohort A: BRAF 26; NRAS 11; WT 20; N/A: 4. Shows chart of 32/33 pos in… https://t.co/JbAnzxoRlb
11:13am May 8th 2019 via Twitter Web Client
Lipson: #oncobeam #genomewebinar 3 cohorts: A single blood draw of met melanoma; B high-risk resected melanoma, ser… https://t.co/f9FdihHLh2
11:11am May 8th 2019 via Twitter Web Client
Lipson: #oncobeam #genomewebinar Aims - est concordance, est clinical LoD. Single-center study at Hopkins; looked a… https://t.co/M4zAOCArOp
11:10am May 8th 2019 via Twitter Web Client
Lipson: #oncobeam #genomewebinar Also shows pt after tumor needle biopsy, shows ctDNA level spiking after the biops… https://t.co/UJ6ioysdNt
11:08am May 8th 2019 via Twitter Web Client
Lipson: #oncobeam #genomewebinar Shows increasing levels of ctDNA correlate w/radiographic disease progression. GEC… https://t.co/M3yOpHOAfS
11:06am May 8th 2019 via Twitter Web Client
Lipson: #oncobeam #genomewebinar Only two mutations (BRAF and NRAS) represent 50% and 30% of recurrence in melanoma… https://t.co/yW2LQvHRkL
11:05am May 8th 2019 via Twitter Web Client
Lipson: #oncobeam #genomewebinar Starts with a patient stroy - primary, regional recurrence, and distant mets. LDH… https://t.co/4KrjgVxcyo
11:04am May 8th 2019 via Twitter Web Client
Evan Lipson (Johns Hopkins Kimmel CC) Liquid monitoring - optimizing melanoma detection using ctDNA #oncobeam #genomewebinar
11:02am May 8th 2019 via Twitter Web Client
Evan Lipson (Johns Hopkins Kimmel CC) and Stefan Holdenrieder (Technical University of Munich) presenting an… https://t.co/Kui6oM2MKx
11:00am May 8th 2019 via Twitter Web Client
Live Webinar Wed May 8 11am ET OncoBEAM ctDNA Testing for Early Response Prediction and Therapy Surveillance in Mel… https://t.co/CwXVUjZmuq
10:39am May 8th 2019 via Twitter Web Client
RT @DaleYuzuki: Interested in how digital PCR is used to analyze circulating tumor DNA (ctDNA) as a liquid biopsy for early response predic…
9:39am May 8th 2019 via Twitter Web Client
Interested in how digital PCR is used to analyze circulating tumor DNA (ctDNA) as a liquid biopsy for early respons… https://t.co/75SMeVNBtd
8:34am May 6th 2019 via Buffer
Silicon Valley's health-tech start-ups need to stop getting in so much trouble | MSN https://t.co/Mtie04orFW
7:31am May 6th 2019 via Buffer
Pacific Biosciences Q1 Revenues Fall 15 Percent | GenomeWeb https://t.co/4Rsb4FHbgn
6:24am May 6th 2019 via Buffer
RT @ArimaGenomics: Humbled and proud to be one of the #SBIR success stories. Please follow us as we continue the journey celebrating scien…
8:11pm May 5th 2019 via Twitter Web Client
Interested in how digital PCR is used to analyze circulating tumor DNA (ctDNA) as a liquid biopsy for early respons… https://t.co/rpPhaXaQ8g
9:03pm May 4th 2019 via Twitter Web Client
Understanding NGS Library Complexity: Sources of Sequencing Errors & Limits of Detection - SeqOnce https://t.co/RWTbpTcnH8
2:17pm May 3rd 2019 via Buffer
RT @lydiaramsey125: uBiome's board is looking into the company's billing practices and put its cofounders/co-CEOs o… https://t.co/eT6e44QEvU
8:05pm May 1st 2019 via Hootsuite Inc.
RT @OmicsAcademy: AI Uses Images and Omics to Decode Cancer https://t.co/uwM5WesdsA
7:35pm May 1st 2019 via Hootsuite Inc.
RT @EricTopol: We've been hearing about stem cells for treating disease for so many years. Finally, a 1st rate revi… https://t.co/51M8kJbScV
6:35pm May 1st 2019 via Hootsuite Inc.
RT @DarylGohl: Excited to see our paper on @Illumina size bias out today in @GenomeBiology. https://t.co/5iUDoTeTbb 1/8
5:20pm May 1st 2019 via Hootsuite Inc.
RT @NewsfromScience: As DNA testing gallops ahead, doctors face wrenching questions about legal risks, protecting patients’ privacy, and th…
5:52pm April 30th 2019 via Hootsuite Inc.
NeoGenomics Ordered to Pay Health Discovery $6.6M| GenomeWeb https://t.co/V7DYsk02HG
10:21am April 30th 2019 via Buffer
'Looping' Created an Underground Insulin-Pump Market - The Atlantic https://t.co/1FxUXghBWK
10:15am April 30th 2019 via Hootsuite Inc.
China cash helps Congenica raise extra £13.25m to take Series B to £23.3m | Business Weekly https://t.co/K1ICF1estW
9:20am April 30th 2019 via Buffer
Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors | Nature Comm https://t.co/j0uCd0AWl4
8:15am April 30th 2019 via Buffer
RT @NCIgenomics: How to use 0.1X sequencing to get prognostic information for cancer patients. Discussion with… https://t.co/6VxHCvobma
7:25am April 30th 2019 via Hootsuite Inc.
RT @NatureNews: 1. Publication bias ❌ 2. Low statistical power ❌ 3. P-value hacking ❌ 4. HARKing (hypothesizing after results are known). ❌…
6:13am April 30th 2019 via Hootsuite Inc.
ICYMI: New post: A new role at a cell-free tumor DNA oncology testing company Sysmex-Inostics | The Next Generation… https://t.co/MnfvB0g6T7
7:26am April 29th 2019 via Hootsuite Inc.
@jdidion Thanks John - great to be back!!
7:26am April 29th 2019 via Hootsuite Inc. in reply to jdidion
